Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
AstraZeneca
McKesson
Covington
Citi
Teva
US Army
Julphar
Baxter

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,193,998

« Back to Dashboard

Which drugs does patent 6,193,998 protect, and when does it expire?

Patent 6,193,998 protects DEPODUR and is included in one NDA.

This patent has fourteen patent family members in eight countries.
Summary for Patent: 6,193,998
Title: Method for producing liposomes with increased percent of compound encapsulated
Abstract:The efficiency of encapsulating a drug into a liposomal formulation is increased by use of a lipid having a carbon chain containing from about 13 to about 28 carbons during preparation of the liposomes. Preferably the liposomes are multivesicular liposomes.
Inventor(s): Ye; Qiang (San Diego, CA), Sankaram; Mantripragada Bhima (San Diego, CA)
Assignee: SkyePharma Inc. (San Diego, CA)
Application Number:09/431,523
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,193,998

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pacira Pharms Inc DEPODUR morphine sulfate INJECTABLE, LIPOSOMAL;EPIDURAL 021671-001 May 18, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pacira Pharms Inc DEPODUR morphine sulfate INJECTABLE, LIPOSOMAL;EPIDURAL 021671-002 May 18, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pacira Pharms Inc DEPODUR morphine sulfate INJECTABLE, LIPOSOMAL;EPIDURAL 021671-003 May 18, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,193,998

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,997,899 Method for producing liposomes with increased percent of compound encapsulated ➤ Subscribe
6,171,613 Method for producing liposomes with increased percent of compound encapsulated ➤ Subscribe
6,241,999 Method for producing liposomes with increased percent of compound encapsulated ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,193,998

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 4657997 ➤ Subscribe
Australia 738020 ➤ Subscribe
Canada 2267416 ➤ Subscribe
European Patent Office 1005326 ➤ Subscribe
Israel 129145 ➤ Subscribe
Japan 2001505549 ➤ Subscribe
Japan 2003327525 ➤ Subscribe
Japan 2003327526 ➤ Subscribe
Japan 2003327544 ➤ Subscribe
Japan 2008163040 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Argus Health
Colorcon
McKesson
Cipla
Chinese Patent Office
Daiichi Sankyo
Novartis
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot